EA201390712A1 - Производные пиридазина, композиции и способы лечения когнитивного нарушения - Google Patents
Производные пиридазина, композиции и способы лечения когнитивного нарушенияInfo
- Publication number
- EA201390712A1 EA201390712A1 EA201390712A EA201390712A EA201390712A1 EA 201390712 A1 EA201390712 A1 EA 201390712A1 EA 201390712 A EA201390712 A EA 201390712A EA 201390712 A EA201390712 A EA 201390712A EA 201390712 A1 EA201390712 A1 EA 201390712A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- derivatives
- compositions
- cognitive impairment
- methods
- pyridazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Настоящее изобретение относится к производным пиридазина, композициям, содержащим терапевтически эффективные количества данных производных пиридазина, и способам применения данных производных или композиций при лечении нарушений центральной нервной системы (ЦНС) с когнитивным нарушением, которые реагируют на агонисты содержащего α5 субъединицу ГАМКрецептора, напримервозрастное когнитивное нарушение, умеренное когнитивное нарушение (УКН), деменция, болезнь Альцгеймера (БА), продромальная фаза БА, посттравматическое стрессовое расстройство (ПТСР), шизофрения и связанное с терапией рака когнитивное нарушение.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41397110P | 2010-11-15 | 2010-11-15 | |
PCT/US2011/060854 WO2012068161A1 (en) | 2010-11-15 | 2011-11-15 | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201390712A1 true EA201390712A1 (ru) | 2013-11-29 |
EA027840B1 EA027840B1 (ru) | 2017-09-29 |
Family
ID=46084380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201390712A EA027840B1 (ru) | 2010-11-15 | 2011-11-15 | Производные пиридазина, композиции и способы лечения когнитивного нарушения |
Country Status (12)
Country | Link |
---|---|
US (2) | US9145372B2 (ru) |
EP (2) | EP2640391B1 (ru) |
JP (1) | JP5916746B2 (ru) |
CN (1) | CN103313712B (ru) |
AU (1) | AU2011328993B2 (ru) |
BR (1) | BR112013012062B1 (ru) |
CA (1) | CA2818025A1 (ru) |
DK (2) | DK2640391T3 (ru) |
EA (1) | EA027840B1 (ru) |
MX (1) | MX346185B (ru) |
NO (1) | NO3034079T3 (ru) |
WO (1) | WO2012068161A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO3034079T3 (ru) * | 2010-11-15 | 2018-06-09 | ||
EP2642919A4 (en) * | 2010-11-26 | 2014-10-08 | Brigham & Womens Hospital | METHOD FOR EVALUATING REPETITIVE HEAD INJURY LESIONS USING TWO-DIMENSIONAL MAGNETIC RESONANCE SPECTROSCOPY |
WO2014047413A1 (en) | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
WO2014078377A1 (en) * | 2012-11-14 | 2014-05-22 | Agenebio, Inc. | Methods and compositions for treating schizophrenia |
NZ722077A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
AU2016279052A1 (en) | 2015-06-19 | 2018-02-15 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
TWI697485B (zh) * | 2015-07-21 | 2020-07-01 | 日商捷恩智股份有限公司 | 含唑啉環的化合物、含有其的電子輸送/注入層用材料、使用其的有機電致發光元件、顯示裝置及照明裝置 |
US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
CN112601749B (zh) | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物,组合物和方法 |
JP2022538955A (ja) | 2019-03-19 | 2022-09-07 | ケンブリッジ コグニション リミテッド | 精神障害のための治療の診断および推奨の方法および利用 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
CH603545A5 (ru) | 1972-04-20 | 1978-08-31 | Merz & Co | |
NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
ATE94384T1 (de) | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
EP0478195B1 (en) | 1990-09-21 | 1999-05-26 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones as fungicides |
US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
EP0781768B1 (en) | 1991-05-24 | 2001-11-21 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
TW201311B (ru) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
HU225051B1 (en) | 1994-03-02 | 2006-05-29 | Organon Ireland Ltd | Sublingual or buccal pharmaceutical compositions containing trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole |
US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
AU1041599A (en) | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
CA2349700A1 (en) | 1998-11-12 | 2000-05-18 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
US6677330B1 (en) | 1999-03-03 | 2004-01-13 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
SK10752003A3 (sk) | 2001-03-01 | 2004-08-03 | Pfizer Products Inc. | Použitie inverzných agonistov GABAA v kombinácii s parciálnymi agonistami receptora nikotínu, estrogénom, selektívnymi modulátormi estrogénu alebo vitamínom E pri liečení kognitívnych porúch |
US20050071088A1 (en) | 2001-08-13 | 2005-03-31 | Landfield Philip W | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
WO2003061656A1 (en) | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
EP1532120B1 (en) * | 2002-08-13 | 2009-01-14 | MERCK SHARP & DOHME LTD. | Phenylpyridazine derivatives as ligands for gaba receptors |
GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
TW200418446A (en) | 2002-10-24 | 2004-10-01 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
MXPA05005398A (es) | 2002-11-22 | 2006-03-09 | Univ Johns Hopkins | Meta para terapia de deterioro cognitivo. |
US20050113458A1 (en) | 2003-10-22 | 2005-05-26 | Forest Laboratories, Inc. | Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies |
EP1799224A1 (en) | 2004-09-23 | 2007-06-27 | Merz Pharma GmbH & Co.KGaA | Memantine for the treatment of childhood behavioral disorders |
RU2007112675A (ru) | 2004-10-12 | 2008-11-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ |
NZ554439A (en) | 2004-10-20 | 2009-09-25 | Hoffmann La Roche | Imidazo-benzodiazepine derivatives |
US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
EP1888594A2 (en) | 2005-05-16 | 2008-02-20 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
CA2730148C (en) | 2008-08-01 | 2018-04-03 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
AU2009296852A1 (en) * | 2008-09-24 | 2010-04-01 | E. I. Du Pont De Nemours And Company | Fungicidal pyridazines |
EP3378310B1 (en) | 2008-09-25 | 2021-08-04 | Vive Crop Protection Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
WO2010120370A2 (en) | 2009-04-17 | 2010-10-21 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as gabab receptor ligands |
EP2523944A4 (en) | 2010-01-11 | 2013-06-19 | Mithridion Inc | COMPOUNDS AND COMPOSITIONS FOR IMPROVING COGNITION, METHODS OF MAKING THE SAME, AND METHODS OF TREATMENT |
BR112013012072A2 (pt) | 2010-11-15 | 2016-08-16 | Agenebio Inc | derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos |
NO3034079T3 (ru) | 2010-11-15 | 2018-06-09 | ||
WO2012161133A1 (ja) * | 2011-05-20 | 2012-11-29 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
WO2014039920A1 (en) | 2012-09-10 | 2014-03-13 | Lewin Matthew R | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
NZ722077A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
-
2011
- 2011-11-15 NO NO15187794A patent/NO3034079T3/no unknown
- 2011-11-15 CA CA2818025A patent/CA2818025A1/en not_active Abandoned
- 2011-11-15 JP JP2013539003A patent/JP5916746B2/ja active Active
- 2011-11-15 EP EP11841746.8A patent/EP2640391B1/en active Active
- 2011-11-15 DK DK11841746.8T patent/DK2640391T3/da active
- 2011-11-15 BR BR112013012062-2A patent/BR112013012062B1/pt not_active IP Right Cessation
- 2011-11-15 WO PCT/US2011/060854 patent/WO2012068161A1/en active Application Filing
- 2011-11-15 AU AU2011328993A patent/AU2011328993B2/en not_active Ceased
- 2011-11-15 MX MX2013005442A patent/MX346185B/es active IP Right Grant
- 2011-11-15 EA EA201390712A patent/EA027840B1/ru not_active IP Right Cessation
- 2011-11-15 EP EP15187794.1A patent/EP3034079B1/en active Active
- 2011-11-15 DK DK15187794.1T patent/DK3034079T3/en active
- 2011-11-15 CN CN201180063261.2A patent/CN103313712B/zh not_active Expired - Fee Related
- 2011-11-15 US US13/885,569 patent/US9145372B2/en not_active Expired - Fee Related
-
2015
- 2015-09-18 US US14/858,959 patent/US9801879B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2640391B1 (en) | 2015-11-11 |
EA027840B1 (ru) | 2017-09-29 |
MX346185B (es) | 2017-03-10 |
WO2012068161A1 (en) | 2012-05-24 |
DK3034079T3 (en) | 2018-02-05 |
AU2011328993B2 (en) | 2017-03-02 |
NO3034079T3 (ru) | 2018-06-09 |
EP3034079A1 (en) | 2016-06-22 |
JP5916746B2 (ja) | 2016-05-11 |
CN103313712B (zh) | 2016-10-26 |
US20130237545A1 (en) | 2013-09-12 |
CA2818025A1 (en) | 2012-05-24 |
US9145372B2 (en) | 2015-09-29 |
MX2013005442A (es) | 2013-10-03 |
JP2013542267A (ja) | 2013-11-21 |
US20160008357A1 (en) | 2016-01-14 |
DK2640391T3 (da) | 2016-02-15 |
BR112013012062B1 (pt) | 2020-06-02 |
US9801879B2 (en) | 2017-10-31 |
CN103313712A (zh) | 2013-09-18 |
EP3034079B1 (en) | 2018-01-10 |
EP2640391A4 (en) | 2014-05-07 |
BR112013012062A2 (pt) | 2016-08-16 |
EP2640391A1 (en) | 2013-09-25 |
AU2011328993A1 (en) | 2013-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390712A1 (ru) | Производные пиридазина, композиции и способы лечения когнитивного нарушения | |
EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
TN2018000322A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
EA201001696A1 (ru) | СОЕДИНЕНИЯ ХИНУКЛИДИНА В КАЧЕСТВЕ ЛИГАНДОВ НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА α7 | |
EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
PH12017501588A1 (en) | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | |
MX342477B (es) | Compuestos y su uso como inhibidores de sitio beta de escision de enzima (bace). | |
TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
EA201390971A1 (ru) | ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ | |
EA202190076A1 (ru) | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений | |
EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
MX2019010577A (es) | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro cognitivo. | |
EA201290244A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10 | |
MX2017006049A (es) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidro piridinas como inhibidores de bace1. | |
WO2009158467A3 (en) | Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors | |
MX2014006752A (es) | Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina. | |
EA201991497A1 (ru) | Производные бензодиазепина, композиции и способы лечения когнитивного нарушения | |
MY165209A (en) | 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
EA201890090A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
EA201290764A1 (ru) | Способы и композиции для улучшения когнитивной функции | |
TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
PH12020551779A1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
WO2010080757A3 (en) | Combinations with an alpha-4beta-2 nicotinic agonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |